Melanoma follow-up care

Leiter U, Keim U, Garbe C (2020) Epidemiology of skin cancer: Update 2019. Adv Exp Med Biol 1268:123–139

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N et al (2022) European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. Eur J Cancer 170:236–255

Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T et al (2013) Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma”. J Dtsch Dermatol Ges 11(Suppl 6):1–116

Bradford PT, Freedman DM, Goldstein AM, Tucker MA (2010) Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 146:265–272

Menzies S, Barry R, Ormond P (2017) Multiple primary melanoma: a single centre retrospective review. Melanoma Res 27:638–640

Dreno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L et al (2017) Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol 28:1137–1144

Wang SQ, Kopf AW, Koenig K, Polsky D, Nudel K, Bart RS (2004) Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy. J Am Acad Dermatol 50:15–20

Trotter SC, Sroa N, Winkelmann RR, Olencki T, Bechtel M (2013) A global review of melanoma follow-up guidelines. J Clin Aesthet Dermatol 6:18–26

Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P et al (2005) Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41:28–44

Goldstein AM, Tucker MA (2013) Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev 22:528–532

Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB (2010) Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 28:3042–3047

Leiter U, Buettner PG, Eigentler TK, Bröcker EB, Voit C, Gollnick H et al (2012) Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol 66:37–45

Jones DV Jr., Ajani JA, Blackburn R, Daugherty K, Levin B, Patt YZ et al (1992) Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs 10:211–213

Stucky CC, Gray RJ, Dueck AC, Wasif N, Laman SD, Sekulic A et al (2010) Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am J Surg 200:770–774 (discussion 774–775)

Goggins WB, Tsao H (2003) A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 97:639–643

Moloney FJ, Guitera P, Coates E, Haass NK, Ho K, Khoury R et al (2014) Detection of primary melanoma in individuals at extreme high risk: a prospective 5‑year follow-up study. JAMA Dermatol 150:819–827

Rueth NM, Cromwell KD, Cormier JN (2015) Long-term follow-up for melanoma patients: is there any evidence of a benefit? Surg Oncol Clin N Am 24:359–377

Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L et al (2022) Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts: implications for Adjuvant treatment. J Clin Oncol 40:3741–3749

Husson O, Holterhues C, Mols F, Nijsten T, van de Poll-Franse LV (2010) Melanoma survivors are dissatisfied with perceived information about their diagnosis, treatment and follow-up care. Br J Dermatol 163:879–881

Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V et al (2022) Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 399:1718–1729

Livingstone E, Krajewski C, Eigentler TK, Windemuth-Kieselbach C, Benson S, Elsenbruch S et al (2015) Prospective evaluation of follow-up in melanoma patients in Germany—Results of a multicentre and longitudinal study. Eur J Cancer 51:653–667

Rychetnik L, McCaffery K, Morton R, Irwig L (2013) Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature. Psychooncology 22:721–736

Rychetnik L, McCaffery K, Morton RL, Thompson JF, Menzies SW, Irwig L (2013) Follow-up of early stage melanoma: specialist clinician perspectives on the functions of follow-up and implications for extending follow-up intervals. J Surg Oncol 107:463–468

Kruijff S, Hoekstra HJ (2012) The current status of S‑100B as a biomarker in melanoma. Eur J Surg Oncol 38:281–285

Kruijff S, Bastiaannet E, Suurmeijer AJ, Hoekstra HJ (2010) Detection of melanoma nodal metastases; differences in detection between elderly and younger patients do not affect survival. Ann Surg Oncol 17:3008–3014

Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE et al (2011) Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 103:129–142

Ribero S, Podlipnik S, Osella-Abate S, Sportoletti-Baduel E, Manubens E, Barreiro A et al (2017) Ultrasound-based follow-up does not increase survival in early-stage melanoma patients: A comparative cohort study. Eur J Cancer 85:59–66

Podlipnik S, Carrera C, Sanchez M, Arguis P, Olondo ML, Vilana R et al (2016) Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. J Am Acad Dermatol 75:516–524

Riquelme-Mc Loughlin C, Podlipnik S, Bosch-Amate X, Riera-Monroig J, Barreiro A, Espinosa N et al (2019) Diagnostic accuracy of imaging studies for initial staging of T2b-T4b melanoma patients. A cross-sectional study. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2019.05.076

Podlipnik S, Moreno-Ramírez D, Carrera C, Barreiro A, Manubens E, Ferrandiz-Pulido L et al (2019) Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma. Br J Dermatol 180:1190–1197

Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE et al (2019) Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 80:208–250

NICE (2022) Evidence reviews for the follow-up of people with melanoma: Melanoma: assessment and management: Evidence review G. NICE Evidence Reviews Collection, Bd. 2022. National Institute for Health and Care Excellence (NICE), London